The overexpression of long intergenic ncRNA00162 induced by RelA/p65 promotes growth of pancreatic ductal adenocarcinoma.


Journal

Cell proliferation
ISSN: 1365-2184
Titre abrégé: Cell Prolif
Pays: England
ID NLM: 9105195

Informations de publication

Date de publication:
May 2020
Historique:
received: 07 09 2019
revised: 15 03 2020
accepted: 18 03 2020
pubmed: 5 5 2020
medline: 17 6 2020
entrez: 5 5 2020
Statut: ppublish

Résumé

Recent observations have emphasized the role of long non-coding RNA (lncRNA) in cancer progression; however, a genetic profile of lncRNAs in pancreatic ductal adenocarcinoma (PDAC) remains an ongoing study. In this research, RNA sequencing showed that LINC00162 is dramatically increased in patient-derived tumour cell lines (PATC) compared with the human pancreatic nestin-positive epithelial (HPNE) cells. These data were validated in several PDAC cell lines, and significant upregulation of LINC00162 was found in all of them. Knock-down of LINC00162 significantly inhibited the proliferation, colony formation and migration of PATC cells in vitro and suppressed the growth of PATC xenografts in vivo. Overexpression of LINC00162 in PDAC cell lines (AsPc-1) showed consistent results, with significantly increased proliferation, colony formation and migration of AsPc-1 cells, as well as enhanced tumour growth of the AsPc-1 xenografts in vivo. Furthermore, the result of Chromatin immunoprecipitation assay revealed that RelA/p65 directly bound to LINC00162, and the expression of LINC00162 in PDAC decreased after RelA/p65 knock-down, the proliferation ability of AsPc-1 also significantly inhibited after knocking down LINC00162 and RelA/p65 simultaneously, indicating that RelA/p65 directly involve in the transcriptional regulation of LINC00162. In sum, our results provide first evidence for the role of LINC00162 in promoting PDAC progression and the potential underlying mechanism of LINC00162 overexpression.

Identifiants

pubmed: 32364285
doi: 10.1111/cpr.12805
pmc: PMC7260071
doi:

Substances chimiques

RELA protein, human 0
RNA, Long Noncoding 0
Transcription Factor RelA 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12805

Subventions

Organisme : National Natural Science Foundation of Guangxi
ID : 2018GXNSFAA281123
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : Key laboratory of early prevention and treatment of regional high-incidence tumours, ministry of education
ID : GKE2017-ZZ03
Organisme : National Natural Science Foundation of China
ID : 81460431
Organisme : NCI NIH HHS
ID : R01 CA207031
Pays : United States
Organisme : Key laboratory of early prevention and treatment of regional high-incidence tumours, ministry of education
ID : GJZ201604
Organisme : Guangxi Health Department Self Financing Research Project
ID : Z20190218

Informations de copyright

© 2020 The Authors. Cell Proliferation published by John Wiley & Sons Ltd.

Références

Database (Oxford). 2013 Jul 11;2013:bat034
pubmed: 23846593
Cancer Lett. 2016 Aug 28;379(1):1-11
pubmed: 27233476
Cell. 2018 Jul 26;174(3):564-575.e18
pubmed: 30033362
Oncogene. 2003 Mar 6;22(9):1365-70
pubmed: 12618762
Oncogene. 2018 Feb 15;37(7):912-923
pubmed: 29059173
J Invest Dermatol. 2016 Aug;136(8):1701-1710
pubmed: 27049681
PLoS One. 2014 Jul 16;9(7):e101452
pubmed: 25029561
Clin Cancer Res. 2007 Jun 1;13(11):3133-9
pubmed: 17545515
Nat Genet. 2011 Dec 11;44(1):62-6
pubmed: 22158540
Nat Commun. 2017 Feb 24;8:14437
pubmed: 28232723
Clin Cancer Res. 2013 Feb 1;19(3):549-59
pubmed: 23340292
Cell Physiol Biochem. 2017;44(2):804-816
pubmed: 29176322
Genes Chromosomes Cancer. 2012 Jun;51(6):579-89
pubmed: 22334418
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
J Natl Cancer Inst. 2011 Aug 3;103(15):1190-204
pubmed: 21743023
Cell Prolif. 2020 May;53(5):e12805
pubmed: 32364285
Nature. 2010 Apr 15;464(7291):1071-6
pubmed: 20393566
Cancer Res. 2018 Jul 15;78(14):3849-3864
pubmed: 29844127
Cancer Discov. 2011 Jul;1(2):103-5
pubmed: 22586351
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Int J Cancer. 2008 Oct 15;123(8):1807-15
pubmed: 18649361
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Cancer Cell. 2012 Jan 17;21(1):105-20
pubmed: 22264792
Clin Cancer Res. 2000 Aug;6(8):2969-72
pubmed: 10955772
Cancer Res. 2016 Nov 15;76(22):6543-6554
pubmed: 27659045

Auteurs

Yu Lu (Y)

Department of Clinical Laboratory, Liuzhou People's Hospital, Liuzhou, China.
Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Min Wu (M)

Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jie Fu (J)

Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Yichen Sun (Y)

Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Kenei Furukawa (K)

Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jianhua Ling (J)

Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Xue Qin (X)

Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Paul J Chiao (PJ)

Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH